PAVmed, Inc.

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Medical Specialties
TMOThermo Fisher Scientific, Inc. -0.71%413.661.0%$505.58m
DHRDanaher Corp. -0.61%205.930.7%$474.62m
ISRGIntuitive Surgical, Inc. -0.77%685.222.4%$447.43m
ABTAbbott Laboratories -0.81%100.280.8%$445.01m
MDTMedtronic Plc -0.27%101.020.6%$437.66m
DXCMDexCom, Inc. -1.37%429.307.9%$349.49m
BDXBecton, Dickinson & Co. -0.83%260.151.0%$331.52m
VARVarian Medical Systems, Inc. -0.05%173.169.1%$316.03m
INOInovio Pharmaceuticals, Inc. 2.17%14.705.9%$314.48m
BSXBoston Scientific Corp. -1.64%39.101.0%$296.69m
BAXBaxter International, Inc. -0.73%84.021.8%$271.78m
ALGNAlign Technology, Inc. -1.44%307.746.4%$251.75m
SYKStryker Corp. -1.59%187.931.3%$246.08m
QDELQuidel Corp. -1.86%244.728.1%$197.73m
EWEdwards Lifesciences Corp. -1.61%78.130.4%$196.67m

Company Profile

PAVmed, Inc. is a medical device company, which develops and commercializes a pipeline of medical products. Its product portfolio includes DisappEAR, PORTIO, Caldus, Carpx, NextCath, and NextFlo. The firm conducts its operations in four divisions: GI Health, Minimally Invasive Interventions, Infusion Therapy and Emerging Innovations. The GI Health division consists of Edouard Esophageal DNA Test, EsoCheck Esophageal Cell Collection Device, and EsoCure Esophageal Ablation Device with Caldus Technology. The Minimally Invasive Interventions division consists of CarpX, which is a patented, single-use disposable, minimally invasive device designed to treat carpal tunnel syndrome. The Infusion Therapy division consists of PortIO, which is a novel, patented, implantable, intraosseous vascular medical device; and NextFlo, which is designed to deliver gravity-driven infusions independent of the height of the IV bag. The Emerging Innovations division refers to a diversified and expanding portfolio of innovative products designed to address unmet clinical needs across a broad range of clinical conditions. The company was founded on June 26, 2014 and is headquartered in New York, NY.